pegol-sihematide
Peptideexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02619097)
Timeline
Indications
Mechanism of action
- ErythropoietinSupplementation
EPO supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pegol-sihematide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03902691 | Phase 3 | May 16, 2019 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Zhejiang University |
| NCT03903809 | Phase 3 | May 1, 2019 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Zhejiang University |
| NCT02586402 | Phase 2 | Oct 1, 2015 | Jiangsu Hansoh Pharmaceutical Co., Ltd., People's Liberation Army of China |
| NCT02619097 | Phase 1 | Jun 1, 2014 | Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 4 | 4 | 3 | 2014 |
| Zhejiang University | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2014 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1